biotech / news / / The Manila Times
Preclinical data on Caliway's localized fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies were presented in an oral presentation at the European Congress on Obesity 2026 (ECO 2026) on May 14.
CBL-514 combined with semaglutide increased body weight reduction by 91.5% versus semaglutide alone in animals.
KEY POINTS
- CBL-514 plus tirzepatide halved post-discontinuation weight regain compared to tirzepatide monotherapy in animal studies.
- CBL-514 combinations produced 182.5% more subcutaneous and 367.4% more visceral fat reduction post-therapy.
- This was the first public disclosure of CBL-514 improving liver lipid and cholesterol indicators in animal models.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →